Interesting Image

A Case with ⁶⁸Ga-FAPI Positive and ¹⁸F-FDG Negative Breast Cancer

10.4274/mirt.galenos.2021.69926

• Halil Kömek
• Cihan Gündoğan
• Hülya Etem
• Canan Can

Received Date: 18.05.2021 Accepted Date: 08.07.2021 Mol Imaging Radionucl Ther 2021;30(3):201-204 PMID: 34661066

• Abstract
• Full Text
• Video - Image
• References
• 13
• 1042

A female patient diagnosed of infiltrative breast carcinoma using tru-cut biopsy underwent ¹⁸flourine-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) for staging. The tumor was located in the superior external quadrant of the right breast, and did not exhibit pathological uptake in ¹⁸F-FDG PET/CT. Later, gallium-⁶⁸ (⁶⁸Ga) fibroblast activation protein-specific inhibitor (FAPI)-04 PET/CT imaging was performed and the primary tumor showed intense radiotracer accumulation. This presumes that ⁶⁸Ga-FAPI PET/CT imaging is superior to ¹⁸F-FDG imaging in detecting the primary tumor in breast cancer, thereby suggesting the replacement of FAPI by ¹⁸F-FDG in breast-cancer staging in the future.

Keywords: 68Ga-FAPI, 18F-FDG, PET/CT, breast cancer

Ethics

Informed Consent: Written informed consent was obtained from the patient.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: H.K., C.G., H.E., C.C., Concept: H.K., C.G., H.E., C.C., Design: H.K., C.G., H.E., C.C., Data Collection or Processing: H.K., C.G., H.E., C.C., Analysis or Interpretation: H.K., C.G., H.E., C.C., Literature Search: H.K., C.G., H.E., C.C., Writing: H.K., C.G., H.E., C.C.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

Images

1. Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med 2019;60:801-805.
2. Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 2020;47:1820-1832.
3. Pang Y, Zhao L, Chen H. 68Ga-FAPI Outperforms 18F-FDG PET/CT in Identifying Bone Metastasis and Peritoneal Carcinomatosis in a Patient With Metastatic Breast Cancer. Clin Nucl Med 2020;45:913-915.
4. Can C, Gündoğan C, Güzel Y, Kaplan İ, Kömek H. 68Ga-FAPI Uptake of Thyroiditis in a Patient With Breast Cancer. Clin Nucl Med 2021;46:683-685.
5. Gündoğan C, Güzel Y, Can C, Alabalik U, Kömek H. False-Positive 68Ga-Fibroblast Activation Protein-Specific Inhibitor Uptake of Benign Lymphoid Tissue in a Patient With Breast Cancer. Clin Nucl Med 2021;46:e433-e435.
6. Kömek H, Can C, Güzel Y, Oruç Z, Gündoğan C, Yildirim ÖA, Kaplan İ, Erdur E, Yıldırım MS, Çakabay B. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT. Ann Nucl Med 2021;35:744-752.